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Entecavir is a nucleoside analog, which is used for the treatment
of chronic hepatitis B. It is a potent and highly selective inhibitor of
DNA polymerase, with a high antiviral efﬁcacy and high genetic
barrier to viral resistance.1,2 Several common side effects of enteca-
vir such as headache, stomachache, and upper respiratory tract
infection have been reported, but cutaneous side effects are
extremely rare and have been reported in only 3 cases in the En-
glish literature.3e5 Herewe report a very unusual case of drug erup-
tion caused by entecavir.
A 65-year-old manwas referred to us for consultation regarding
a bilateral eruption on his arms. He had a history of chronic renal
failure spanning more than 40 years. He had undergone a renal
transplantation at the age of 24 years, and received treatment
with azathioprine (100 mg daily), prednisolone (5 mg daily), and
nifedipine. He had developed a hepatitis B virus (HBV) infection
and had been taking 0.5 mg entecavir daily. Six months after taking
entecavir, he developed bilateral erythematous plaques on his arms
(Fig. 1a). Multiple papillomatous plaques on the arms were verruca
vulgaris often seen in the patients after organ transplantation. Lab-
oratory examination revealed increased white blood cell count,
8600/mL (normal range, 3400e7300/mL) without eosinophilia;
elevated cholinesterase level, 531 U/L (normal range, 206e476 U/
L); and decreased estimated glomerular ﬁltration rate, 45.86 mL/
min/1.73 m2 (normal range, >90 mL/min/1.73 m2). SerologicalFig. 1.. (a) Clinical ﬁndings. Pruritic erythematous plaques on the right arm. (b) Histopatholo
inﬁltration with mild vacuolar alteration (hematoxylin and eosin staining, original magniﬁc
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licenses/by-nc-nd/4.0/).test results for the HBV surface antigen and its antibodies were
both positive. Histological examination of a punch biopsy specimen
from the left forearm revealed superﬁcial perivascular lymphocytic
inﬁltrates with mild vacuolar alteration, which was consistent with
a drug eruption (Fig. 1b). Initially, we suspected drug-induced
photosensitivity due to nifedipine. However, lesions did not
improve even after discontinuation of nifedipine. Minimal ery-
thema doses for UVA and UVB were within normal limits. A drug
lymphocyte stimulation test (DLST) results with nifedipine was
negative. Based on these results, we suspected that the drug erup-
tion was due to entecavir. DLST with entecavir was performed and
the result was positive with a stimulation index of 4.0. Based on the
clinical course and the result of DLST, we diagnosed drug eruption
caused by entecavir. As the eruption was not severe and entecavir
seemed to be effective against HBV, entecavir was not discontinued
but reduced to 0.5 mg every second day, and topical corticosteroid
treatment was initiated. The eruption gradually improved but did
not completely disappear (Fig. 1c).
Only 3 cases of drug eruption caused by entecavir have been re-
ported previously in the literature (Table 1). We reviewed the cases
of 3 men and 1 woman, including our patient. The median age of
onset was 63.5 years. The types of eruptions included immediate al-
lergy,3 maculopapular type,4 granulomatous type5 and erythema-
tous type (our patient). The interval between the start of
entecavir administration and the onset of symptoms varied in
range from 2 days to 6 months.gical ﬁndings of erythematous plaque, which show superﬁcial perivascular lymphocytic
ation 200). (c) Clinical ﬁndings 1 month after reduction of entecavir.
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Table 1
Cases of drug eruption due to entecavir.
Ref. Case no Year Age Sex Clinical manifestations Time intervaly Treatment Patch test DLST Scratch test Recurrrence
3 1 2009 30 M Immediate allergy 2 d Discontinuation, Topical steroid,
Oral anti-histamine
e nw þ nw
4 2 2011 62 M Maculopapular 7 d Discontinuation, Topical steroid nw þ ND nw
5 3 2013 65 F Granulomatous 2 m Discontinuation, Topical metronidazol,
Oral minocycline
e nw nw þ
(3 months after
retreatment)
Our case 4 2014 65 M Erythematous plaque 6 m Reduce,
Topical steroid
ND þ ND þ
Ref, reference; DLST, drug lymphocyte stimulation test; M, male; F, female; d, day; m, month; nw, not written; ND, not done.
y Time interval means between start of entecavir and onset of symptoms.
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one of the key factors in the development of drug eruption.6 Zhang
JYet al.7 reported frequencies of Tregs gradually decreased from the
baseline to month 6 in patients undergoing entecavir treatment,
and the ratio of Tregs to Th17 cells were the lowest at month 3
and exhibited a reverse “V”-type change. We speculated that
long-term duration to onset in this case might be caused by this
gradually decreased Tregs and also the immunosuppressive effects
of azathioprine and prednisolone.
Another interesting observation is that, although entecavir has
been used worldwide, all 4 cases were from East Asian countries.
Recently, the relationship between the genetic background and
drug eruptions has attracted considerable attention.8,9,10 For
example, in the case of carbamazepine-induced StevenseJohnson
syndrome and toxic epidermal necrolysis, a strong association of
HLA-B*1502 and HLA-B*1511, both of which are alleles of the
HLA-B75 serotype, has been found in Han Chinese and Japanese pa-
tients, respectively.8,9 However, these HLA alleles are not found in
Caucasian populations. In addition, HLA-B*5801 has been reported
to be a risk factor for allopurinol-induced StevenseJohnson syn-
drome/toxic epidermal necrolysis.10
According to these observations, which suggest that certain HLA
alleles could be genetic markers for certain drug eruptions, we
could speculate that genetic differences might contribute to a
distinctive hypersensitivity rate for entecavir. Further investigation
is indispensable to determine whether this speculation is correct.
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